On 5/10/24, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) stock suffered a major decline of -10.7%, closing at $22.08. Moreover, this decline was accompanied by exceptionally high trading volume at 243% of normal. The stock has been weak relative to the market over the last nine months and has declined -8.5% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ARWR is expected to continue to be Value Creation neutral.
Arrowhead Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Arrowhead Pharmaceuticals has a neutral Power Rating of 48 but a very low Appreciation Score of 4, leading to the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment